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Case Report-Right iliac fossa mass in an HIV-positive 
woman
A 35 year old woman was admitted to Queen Elizabeth Central 
Hospital (QECH) with fever, abdominal pain and vomiting 
for 3 days. A week earlier she had started antiretroviral therapy 
(ART) in a clinical trial in Blantyre, Malawi, after meeting all 
the requirements of  the study. At the time of  enrolment, her 
CD4 count was 19/μl, and viral load >400,000 copies/ml. 
She was started on a combination of  amtricitabine (FTC), 
tenofivir (TDF) and atazanavir (ATV). 
At the present admission, she looked ill.  Her axillary 
temperature was 38ºC, blood pressure 110/70 mmHg, 
pulse rate 100/minute, weight 56Kg. The abdomen was 
tender to touch without any palpable enlarged organs. A 
full blood count showed a haemoglobin concentration of  
9.8g/dl, other parameters being within normal limits.  Blood 
biochemistry and liver function tests were normal. A blood 
sample for culture was taken which remained sterile after 7 
days of  incubation.  The patient was started on empirical 
intravenous broad spectrum antibiotic (ceftriaxone 2g once 
a day) for possible sepsis.
Two days later the patient remained ill and examination now 
revealed a right iliac fossa mass which was tender to touch. 
A bimanual pelvic examination suggested that the mass was 
arising from the pelvis. A gynecological review confirmed 
the findings. An ultrasound of  the abdomen and pelvis 
identified a mass arising from the pelvis but was unable to 
define the organ of  origin.  Intravenous metronidazole was 
added to ceftriaxone. After ten days of  antibiotic treatment, 
there was no clinical response. 
The gynecologists decided to take the patient for surgical 
exploration. During the procedure a mass was found affecting 
the ileocaecal junction and the whole of  the ascending colon. 
The visual findings were suggestive of  a carcinoma of  the 
ascending colon with areas of  perforation. A hemi-colectomy 
was done (see figure 1-gross specimen of  the colon)
The patient remained unwell and died two weeks later in 
hospital after repeated breakdown of  the anastomosis site. A 
histology report came out two days after the patient died. 
What is the diagnosis?
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 Figure 2: Histology Specimen stained with Periodic Acid Schiff 
reagent (PAS).
Figure 1: Part of the resected tumor
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Periodic Acid Schiff  reagent (PAS), the stain used on the 
section shown in Figure 2, reacts with large carbohydrate 
molecules such as glycogen and polysaccharides, to produce a 
deep red or purple colour.  It therefore delineates, for example, 
the surface structure of  encapsulated microorganisms. 
In Figure 2, numerous distinct oval bodies can be seen 
throughout the sheet of  tiussue.  These are characteristic of  
the yeast Cryptococcus neoformans.
C neoformans can be isolated from soil and bird habitats. Most 
human infections are thought to be acquired by inhalation 
of  fungus4. Pulmonary infection is usually asymptomatic. 
The organisms spread through the blood system and 
mainly cause meningoencephalitis, but can also affect other 
sites5. Cryptococcosis due to C. neoformans is a common 
complication of  severe immunodepression secondary 
to HIV infection6. Other conditions that predispose to 
cryptococcal infection include solid-organ transplantation 
or glucocorticoid therapy4. All these conditions share one 
common element, defective cell mediated immunity2. 
The most common clinical presentation of  cryptococcosis 
is meningitis, seen in over 70% of  infections. About 6 to 
10% of  HIV infected persons not on prophylactic therapy 
or highly active antiretroviral therapy have been shown to 
develop cryptococcal meningitis in developed nations. More 
than 75% of  the patients have CD4 cell count that is less 
than 50/µL1, 2. Most infections are acquired through the 
respiratory tract, where the major host defense mechanism 
is complement-mediated phagocytosis by macrophages3. In 
about a third to half  of  cryptococcal infections, there is a 
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pneumonitis. Pulmonary involvement is usually seen with 
dissemination, though isolated pulmonary disease may 
be present. Fever, cough, and dyspneoa are non-specific 
manifestations of  pulmonary cryptococcosis. Other clinically 
apparent lesions may be seen on skin and in the eye4. 
Cryptococcal meningitis is the commonest cause of  adult 
meningitis in Malawians infected with HIV-1 contributing 
almost 60% of  all proven adult meningitis cases at QECH 
(WTL unpublished data).  Intra-abdominal cryptococcosis 
however is rare.
This case is exceptional, not because a patient with severe 
HIV immunodepression developed cryptococcal infection 
but because the patient developed what looked like colonic 
carcinoma. There have been very few case reports to date of  
AIDS patients developing abdominal cryptococossis7, 8 and 
even fewer case reports in HIV uninfected individuals9. Our 
case is among the few and we believe it contributes to the 
body of  knowledge in this area. 
Other unusual predisposing factors to mesenteric 
cryptococcosis include SLE10. There has been one report 
of  immuno-competent children developing mesenteric 
cryptococcosis11.
The development of  a sudden right iliac fossa mass on the 
background of  10 days of  HAART is difficult to explain. 
The mass developed too soon after starting ART to be 
considered an immune reconstitution syndrome. The mass 
may have been present earlier and missed during the original 
examination. Furthermore, a CD4 cell count performed two 
weeks after starting ART (at this point the patient was already 
admitted to the hospital) remained unchanged. If  CD4 count 
had increased above baseline, immune reconstitution would 
be a possible explanation.
The host defense mechanisms protecting the body against 
cryptococcal infections are complex and not completely 
understood. Cell-mediated immunity (CMI) is the crucial 
component of  the immune system for resistance against 
cryptococcosis, and its impairment presumably accounts 
for the high incidence of  invasive cryptococcal infections 
in patients with HIV-AIDS.  Other impairments of  host 
defence may also contribute to susceptibility to crypotococcal 
invasion, as in a female SLE patient described by Mok et 
al, who developed cryptococcal meningitis concurrently 
with active SLE and in the absence of  immunosuppressive 
treatment or other predisposing conditions12. They 
suggested that her low complement level, low natural killer 
cell count and the probable defective CD4 positive T cell 
and macrophage functions resulting from her SLE disease 
activity might have been responsible for her susceptibility to 
cryptococcal meningitis12,13,14. 
Conclusion.
This 35 year old woman with severe HIV immunodepression 
presented with fever, abdominal pain, colonic inflammation 
and mesenteric lymphadenopathy which turned out to 
be due to colonic cryptococcosis. This is not a common 
diagnosis even in HIV infected individuals. Tuberculosis 
comes to mind more readily. We would like to suggest that 
Cryptococcus neoformans infection should be considered 
in the differential diagnosis of  fever and marked abdominal 
lymphadenopathy in patients with AIDS.  Where diagnostic 
facilities are limited empirical administration of  antifungal 
agents may be necessary.
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